News Servier to acquire Danish cancer biotech Symphogen France’s Servier has signed a deal to buy the Danish biotech Symphogen, which specialises in antibody-based therapies for cancer.
Sales & Marketing Sponsored Servier reveal how they are using data to empower their fiel... The French independent pharmaceutical Servier is putting data at the foundation of its customer relationship management strategy.
News France's Servier finally goes on trial over Mediator safety ... More than a decade after a scandal over drug safety in France first broke, the pharma company Servier is to go on trial over its weight loss drug Mediator, which is thought to have caused b
News Servier and Oncodesign announce Parkinson's R&D tie-up Servier and Oncodesign have announced a strategic partnership for R&D into potential drug candidates for Parkinson’s disease.
News Servier expands global footprint post Shire deal Following its acquisition of Shire’s oncology business in April, Servier is taking steps to expand its presence in the US and China.
News Shire's $2.4bn oncology sell-off seen as Takeda spoiler Move seen as attempt to fend off Takeda takeover
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
